

# Validation data for Anti-hIL6R-To-hIgG1NQ

<https://www.invivogen.com/anti-il6r-mabs>


For research use only

Version 20G30-ED

Anti-hIL6R-To-hIgG1NQ is a recombinant non-glycosylated monoclonal antibody (mAb) featuring the variable region of the clinically-relevant Tocilizumab (TCZ) and the engineered human IgG1NQ constant region. TCZ specifically binds to both the soluble and membrane-bound human interleukin-6 receptor (hIL-6R). TCZ blocks the binding of IL-6 and thus, inhibits the downstream STAT3-dependent pro-inflammatory response. The inhibitory activity of Anti-hIL6R-To-hIgG1NQ has been validated using InvivoGen's HEK-Blue™ IL-6 cellular assay (Figure 1).

## Inhibition of IL-6 signaling by Anti-hIL6R-To-hIgG1NQ

HEK-Blue™ IL-6 cells were generated by stable transfection of human embryonic kidney 293 (HEK293)-derived cells with the genes encoding human IL-6R and STAT3. Additionally, they encode a STAT3-inducible secreted embryonic alkaline phosphatase (SEAP) reporter gene. Upon IL-6 stimulation, HEK-Blue™ IL-6 cells trigger the activation of STAT3 and the subsequent secretion of SEAP. Anti-hIL6R-To-hIgG1NQ binds to IL-6R and specifically blocks the IL-6 stimulation of these cells in a dose-dependent manner.



**Figure 1: Dose-dependent inhibition of HEK-Blue™ IL-6 cellular response.** Anti-hIL6R-To-hIgG1NQ (0 - 1 µg/ml) was incubated with HEK-Blue™ IL-6 cells for 3 hours. Following this, human (h)IL-6 (0.3 ng/ml) was added to the cells. After overnight incubation, STAT3-dependent SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution, a detection reagent. Data are presented as percentage (%) of the maximum response.

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3-622-34-80

E-mail: [info@invivogen.com](mailto:info@invivogen.com)